Dennis Cho Sells 806 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 806 shares of Twist Bioscience stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $39,776.10. Following the completion of the transaction, the insider now owns 112,221 shares of the company’s stock, valued at $5,538,106.35. This represents a 0.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Dennis Cho also recently made the following trade(s):

• On Friday, January 3rd, Dennis Cho sold 144 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total transaction of $6,564.96.
• On Friday, December 20th, Dennis Cho sold 316 shares of Twist Bioscience stock. The shares were sold at an average price of $44.90, for a total value of $14,188.40.
• On Monday, December 16th, Dennis Cho sold 133 shares of Twist Bioscience stock. The stock was sold at an average price of $46.81, for a total value of $6,225.73.
• On Friday, December 6th, Dennis Cho sold 367 shares of Twist Bioscience stock. The stock was sold at an average price of $52.70, for a total value of $19,340.90.
• On Monday, November 11th, Dennis Cho sold 1,507 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total transaction of $72,336.00.

Twist Bioscience Trading Up 0.1 %

Shares of TWST stock opened at $53.70 on Friday. The business’s 50 day moving average is $48.84 and its two-hundred day moving average is $46.32. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The firm had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. Twist Bioscience’s quarterly revenue was up 24.1% on a year-over-year basis. During the same period last year, the firm posted ($0.75) EPS. On average, research analysts predict that Twist Bioscience Co. will post -2.27 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC boosted its holdings in Twist Bioscience by 83.9% in the 2nd quarter. AQR Capital Management LLC now owns 61,428 shares of the company’s stock valued at $3,027,000 after purchasing an additional 28,027 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Twist Bioscience by 3.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,064 shares of the company’s stock valued at $1,531,000 after buying an additional 1,104 shares during the period. SG Americas Securities LLC boosted its stake in shares of Twist Bioscience by 407.1% in the third quarter. SG Americas Securities LLC now owns 10,958 shares of the company’s stock valued at $495,000 after buying an additional 8,797 shares in the last quarter. CWM LLC boosted its stake in shares of Twist Bioscience by 141.9% in the third quarter. CWM LLC now owns 5,894 shares of the company’s stock valued at $266,000 after buying an additional 3,457 shares in the last quarter. Finally, Exchange Traded Concepts LLC raised its position in Twist Bioscience by 30.1% in the third quarter. Exchange Traded Concepts LLC now owns 20,141 shares of the company’s stock worth $910,000 after acquiring an additional 4,661 shares in the last quarter.

Analyst Upgrades and Downgrades

TWST has been the topic of a number of recent analyst reports. Leerink Partners increased their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. TD Cowen restated a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. Scotiabank lifted their target price on Twist Bioscience from $54.00 to $62.00 and gave the stock a “sector outperform” rating in a research report on Tuesday. Wolfe Research began coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Finally, Robert W. Baird lifted their price target on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $53.80.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.